Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Seminars in Urologic Oncology
|
November 1, 1996
Immunotherapy and gene therapy
B J Gitlitz, A Belldegrun, R A Figlin
Cancer Investigation
|
January 1, 1995
Immunologic approaches to the treatment of cancer
R A Figlin, B J Gitlitz, A Belldegrun
Seminars in Urologic Oncology
|
May 17, 2001
Vaccine and gene therapy of renal cell carcinoma
B J Gitlitz, A S Belldegrun, R A Figlin
Seminars in Oncology
|
April 18, 2000
Adoptive cellular therapy
D M Hoffman, B J Gitlitz, A Belldegrun, et al.
Current Urology Reports
|
June 27, 2002
Dendritic cell-based immunotherapy of renal cell carcinoma
B J Gitlitz, R A Figlin, A J Pantuck, et al.
Cancer Journal (Sudbury, Mass.)
|
April 28, 2001
Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: an analysis of 124 consecutively treated patients
B J Gitlitz, D M Hoffman, N Moldawer, et al.
Cancer Research
|
April 15, 2000
Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients
M D Roth, B J Gitlitz, S M Kiertscher, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
February 25, 2000
Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma
A Hinkel, C L Tso, B J Gitlitz, et al.
The Journal of Urology
|
July 4, 2001
Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome
A Zisman, A J Pantuck, D Chao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2001
Improved prognostication of renal cell carcinoma using an integrated staging system
A Zisman, A J Pantuck, F Dorey, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Seminars in Urologic Oncology
|
November 1, 1996
Immunotherapy and gene therapy
B J Gitlitz, A Belldegrun, R A Figlin
Cancer Investigation
|
January 1, 1995
Immunologic approaches to the treatment of cancer
R A Figlin, B J Gitlitz, A Belldegrun
Seminars in Urologic Oncology
|
May 17, 2001
Vaccine and gene therapy of renal cell carcinoma
B J Gitlitz, A S Belldegrun, R A Figlin
Seminars in Oncology
|
April 18, 2000
Adoptive cellular therapy
D M Hoffman, B J Gitlitz, A Belldegrun, et al.
Current Urology Reports
|
June 27, 2002
Dendritic cell-based immunotherapy of renal cell carcinoma
B J Gitlitz, R A Figlin, A J Pantuck, et al.
Cancer Journal (Sudbury, Mass.)
|
April 28, 2001
Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: an analysis of 124 consecutively treated patients
B J Gitlitz, D M Hoffman, N Moldawer, et al.
Cancer Research
|
April 15, 2000
Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients
M D Roth, B J Gitlitz, S M Kiertscher, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
February 25, 2000
Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma
A Hinkel, C L Tso, B J Gitlitz, et al.
The Journal of Urology
|
July 4, 2001
Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome
A Zisman, A J Pantuck, D Chao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2001
Improved prognostication of renal cell carcinoma using an integrated staging system
A Zisman, A J Pantuck, F Dorey, et al.
Page
of 2